192 related articles for article (PubMed ID: 33675810)
1. NUDT15: A bench to bedside success story.
Moyer AM
Clin Biochem; 2021 Jun; 92():1-8. PubMed ID: 33675810
[TBL] [Abstract][Full Text] [Related]
2. Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients.
Sutiman N; Chen S; Ling KL; Chuah SW; Leong WF; Nadiger V; Tjai M; Choon Kong CS; Schwender BJ; Chan W; Shim HH; Lim WC; Khor CC; Cheung YB; Chowbay B
Pharmacogenomics; 2018 Jan; 19(1):31-43. PubMed ID: 29210335
[TBL] [Abstract][Full Text] [Related]
3. Time to incorporate preemptive NUDT15 testing before starting thiopurines in inflammatory bowel disease in Asia and beyond: a review.
Desai D; Jena A; Sharma V; Hibi T
Expert Rev Clin Pharmacol; 2023; 16(7):643-653. PubMed ID: 37387532
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping.
Kakuta Y; Kinouchi Y; Shimosegawa T
J Gastroenterol; 2018 Feb; 53(2):172-180. PubMed ID: 29192347
[TBL] [Abstract][Full Text] [Related]
5. Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry.
Schaeffeler E; Jaeger SU; Klumpp V; Yang JJ; Igel S; Hinze L; Stanulla M; Schwab M
Genet Med; 2019 Sep; 21(9):2145-2150. PubMed ID: 30728528
[TBL] [Abstract][Full Text] [Related]
6. TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India.
Grover N; Bhatia P; Kumar A; Singh M; Lad D; Mandavdhare HS; Samanta J; Prasad KK; Dutta U; Sharma V
BMC Gastroenterol; 2021 Aug; 21(1):327. PubMed ID: 34425754
[TBL] [Abstract][Full Text] [Related]
7. Role of Pharmacogenomics in the Efficacy and Safety of Thiopurines in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
Gutiérrez-Valencia M; Leache L; Saiz LC; Beloqui JJ; Barajas M; Vicuña M; Erviti J
J Clin Gastroenterol; 2023 Aug; 57(7):671-685. PubMed ID: 36322453
[TBL] [Abstract][Full Text] [Related]
8. A direct sequencing assay for pharmacogenetic testing of thiopurine-intolerant NUDT15 alleles in an Asian population.
Poon KS; Imran IIB; Chew SK; Tan P; Tan KM
BMC Res Notes; 2022 Apr; 15(1):148. PubMed ID: 35468862
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetic determinants of thiopurines in an Indian cohort.
Naushad SM; Janaki Ramaiah M; Kutala VK; Hussain T; Alrokayan SA
Pharmacol Rep; 2021 Feb; 73(1):278-287. PubMed ID: 32935219
[TBL] [Abstract][Full Text] [Related]
10. Nucleoside diphosphate-linked moiety X-type motif 15 C415T variant as a predictor for thiopurine-induced toxicity in Indian patients.
Shah SA; Paradkar M; Desai D; Ashavaid TF
J Gastroenterol Hepatol; 2017 Mar; 32(3):620-624. PubMed ID: 27416873
[TBL] [Abstract][Full Text] [Related]
11. Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations.
Maillard M; Nishii R; Yang W; Hoshitsuki K; Chepyala D; Lee SHR; Nguyen JQ; Relling MV; Crews KR; Leggas M; Singh M; Suang JLY; Yeoh AEJ; Jeha S; Inaba H; Pui CH; Karol SE; Trehan A; Bhatia P; Antillon Klussmann FG; Bhojwani D; Haidar CE; Yang JJ
J Natl Cancer Inst; 2024 May; 116(5):702-710. PubMed ID: 38230823
[TBL] [Abstract][Full Text] [Related]
12. Preemptive NUDT15 genotyping: redefining the management of patients with thiopurine-induced toxicity.
Shah SAV; Paradkar MU; Desai DC; Ashavaid TF
Drug Metab Pers Ther; 2018 Mar; 33(1):57-60. PubMed ID: 29470173
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of polymorphisms in thiopurine metabolism and association with adverse outcomes: a South Asian region-specific systematic review and meta-analysis.
Jena A; Jha DK; Kumar-M P; Kasudhan KS; Kumar A; Sarwal D; Mishra S; Singh AK; Bhatia P; Patil A; Sharma V
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):491-501. PubMed ID: 33682590
[No Abstract] [Full Text] [Related]
14. TPMT and NUDT15 Variants Predict Discontinuation of Azathioprine for Myelotoxicity in Patients with Inflammatory Disease: Real-World Clinical Results.
Dickson AL; Daniel LL; Zanussi J; Dale Plummer W; Wei WQ; Liu G; Reese T; Anandi P; Birdwell KA; Kawai V; Cox NJ; Dupont WD; Hung AM; Feng Q; Stein CM; Chung CP
Clin Pharmacol Ther; 2022 Jan; 111(1):263-271. PubMed ID: 34582038
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive characterization of pharmacogenetic variants in TPMT and NUDT15 in children with acute lymphoblastic leukemia.
Moriyama T; Yang W; Smith C; Pui CH; Evans WE; Relling MV; Bhatia S; Yang JJ
Pharmacogenet Genomics; 2022 Feb; 32(2):60-66. PubMed ID: 34412101
[TBL] [Abstract][Full Text] [Related]
16. Comparison of
Wang HH; He Y; Wang HX; Liao CL; Peng Y; Tao LJ; Zhang W; Yang HX
World J Gastroenterol; 2018 Feb; 24(8):941-948. PubMed ID: 29491687
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogeomic implications of population diversity in Latin America: TPMT and NUDT15 polymorphisms and thiopurine dosing.
Suarez-Kurtz G; Araújo GS; de Sousa SJ
Pharmacogenet Genomics; 2020 Jan; 30(1):1-4. PubMed ID: 31651720
[TBL] [Abstract][Full Text] [Related]
18. NUDT15 polymorphisms are better than thiopurine S-methyltransferase as predictor of risk for thiopurine-induced leukopenia in Chinese patients with Crohn's disease.
Zhu X; Wang XD; Chao K; Zhi M; Zheng H; Ruan HL; Xin S; Ding N; Hu PJ; Huang M; Gao X
Aliment Pharmacol Ther; 2016 Nov; 44(9):967-975. PubMed ID: 27604507
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of pretreatment screening for NUDT15 defective alleles.
Zarca K; Chansavang A; Loriot MA; Durand-Zaleski I; Pallet N
Pharmacogenet Genomics; 2020 Oct; 30(8):175-183. PubMed ID: 32433339
[TBL] [Abstract][Full Text] [Related]
20. Influence of
Kojima Y; Hirotsu Y; Omata W; Sugimori M; Takaoka S; Ashizawa H; Nakagomi K; Yoshimura D; Hosoda K; Suzuki Y; Mochizuki H; Omata M
World J Gastroenterol; 2018 Jan; 24(4):511-518. PubMed ID: 29398872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
